{
  "id": "galad_model_hcc",
  "title": "GALAD Model for Hepatocellular Carcinoma (HCC)",
  "description": "Diagnoses HCC based on serum biomarkers in patients with chronic liver disease (CLD). The GALAD model combines Gender, Age, AFP-L3, AFP, and DCP (des-gamma-carboxy prothrombin) to provide superior diagnostic accuracy compared to individual biomarkers.",
  "category": "oncology",
  "version": "2016",
  "parameters": [
    {
      "name": "age",
      "type": "integer",
      "required": true,
      "description": "Patient's age in years",
      "validation": {
        "min": 18,
        "max": 100
      },
      "unit": "years"
    },
    {
      "name": "sex",
      "type": "string",
      "required": true,
      "description": "Patient's biological sex (males have higher HCC risk)",
      "options": ["male", "female"],
      "validation": {
        "enum": ["male", "female"]
      }
    },
    {
      "name": "afp",
      "type": "float",
      "required": true,
      "description": "Alpha-fetoprotein level in ng/mL. Standard serum tumor marker for HCC evaluation",
      "validation": {
        "min": 0.1,
        "max": 100000
      },
      "unit": "ng/mL"
    },
    {
      "name": "afp_l3_percentage",
      "type": "float",
      "required": true,
      "description": "AFP-L3 percentage (%). Most useful when total AFP ≤200 ng/mL. ≥10% associated with 7-fold increased HCC risk",
      "validation": {
        "min": 0,
        "max": 100
      },
      "unit": "percentage"
    },
    {
      "name": "dcp",
      "type": "float",
      "required": true,
      "description": "Des-gamma-carboxy prothrombin (PIVKA-II) level in mAU/mL. Abnormal prothrombin form used as HCC biomarker",
      "validation": {
        "min": 1,
        "max": 100000
      },
      "unit": "mAU/mL"
    }
  ],
  "result": {
    "name": "galad_score",
    "type": "float",
    "unit": "score",
    "description": "GALAD score calculated from demographic data and serum biomarkers"
  },
  "interpretation": {
    "ranges": [
      {
        "min": -50,
        "max": -0.63,
        "stage": "Low Risk",
        "description": "Low probability of HCC",
        "interpretation": "GALAD score suggests low probability of hepatocellular carcinoma. Continue routine surveillance in high-risk patients."
      },
      {
        "min": -0.63,
        "max": 50,
        "stage": "High Risk",
        "description": "High probability of HCC",
        "interpretation": "GALAD score suggests high probability of hepatocellular carcinoma. Consider further diagnostic imaging and evaluation."
      }
    ]
  },
  "references": [
    "Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23(1):144-53. doi: 10.1158/1055-9965.EPI-13-0870.",
    "Best J, Bechmann LP, Sowa JP, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2020;18(3):728-735.e4. doi: 10.1016/j.cgh.2019.08.012.",
    "Yang JD, Addissie BD, Mara KC, et al. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2019;28(3):531-538. doi: 10.1158/1055-9965.EPI-18-0281."
  ],
  "formula": "Z = -10.08 + 0.09 × age + 1.67 × sex + 2.34 × log₁₀(AFP) + 0.04 × AFP-L3 + 1.33 × log₁₀(DCP), where sex = 1 for males, 0 for females",
  "notes": [
    "Validated in patients with chronic liver disease at risk for HCC",
    "Superior diagnostic accuracy compared to AFP, AFP-L3, or DCP alone (AUC 0.95 vs 0.88, 0.86, 0.87 respectively)",
    "GALAD score ≥-0.63 suggests high probability of HCC with 85.6% sensitivity and 93.3% specificity",
    "Performance superior to ultrasound alone for HCC detection (AUC 0.95 vs 0.82)",
    "Particularly effective for early-stage (BCLC 0/A) HCC detection with AUC 0.92",
    "Use lower limit of quantitation (LLOQ) when biomarker values are below detection limits",
    "Model developed in cohorts with HCC prevalence 35-49%; performance may vary in different populations",
    "Intended for patients with chronic liver disease including cirrhosis, hepatitis B, hepatitis C, NASH"
  ]
}